Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Chronic hyperglycemia impairs insulin action, resulting in glucotoxicity, which can be ameliorated in animal models by inducing glucosuria with renal glucose transport inhibitors. Here, we examined whether reduction of plasma glucose with a sodium-glucose cotransporter 2 (SGLT2) inhibitor could improve insulin-mediated tissue glucose disposal in patients with type 2 diabetes. Eighteen diabetic men were randomized to receive either dapagliflozin (n = 12) or placebo (n = 6) for 2 weeks. We measured insulin-mediated whole body glucose uptake and endogenous glucose production (EGP) at baseline and 2 weeks after treatment using the euglycemic hyperinsulinemic clamp technique. Dapagliflozin treatment induced glucosuria and markedly lowered fasting plasma glucose. Insulin-mediated tissue glucose disposal increased by approximately 18% after 2 weeks of dapagliflozin treatment, while placebo-treated subjects had no change in insulin sensitivity. Surprisingly, following dapagliflozin treatment, EGP increased substantially and was accompanied by an increase in fasting plasma glucagon concentration. Together, our data indicate that reduction of plasma glucose with an agent that works specifically on the kidney to induce glucosuria improves muscle insulin sensitivity. However, glucosuria induction following SGLT2 inhibition is associated with a paradoxical increase in EGP. These results provide support for the glucotoxicity hypothesis, which suggests that chronic hyperglycemia impairs insulin action in individuals with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Long-term effects of sodium-glucose transport protein 2 inhibitors (SGLT2i) might enhance insulin sensitivity, thereby mitigating muscle catabolism and influencing the quality and functionality of the skeletal muscle.30,31”
From Imaging of Sarcopenia in Type 2 Diabetes Mellitus (2024) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425 · cited 2×
“After the start of insulin, no glucose was infused until the plasma glucose concentration declined to 100 mg/dl, at which level it was maintained by the adjustment of a variable glucose infusion based on the negative feedback principle (27).”
Self-citationDeFronzo, R. A., Jacot, E., Jequier, E., Maeder, E., Wahren, J., & Felber, J. P. (1981) · Diabetes · doi:10.2337/diab.30.12.1000 · Cited by 1,770 · cited 1×
“Since >80% of insulin-mediated glucose disposal during the euglycemic insulin clamp takes place in skeletal muscle (16), these results indicate that lowering the plasma glucose concentration in T2DM significantly improves muscle insulin resistance and are consistent with a glucotoxic effect of chronic hyperglycemia to…”
Self-citationMeasurement of Size and Turnover Rate of Body Glucose Pool by the Isotope Dilution Method
Steele, R., Wall, J. S., de Bodo, R. C., & Altszuler, N. (1956) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1956.187.1.15 · Cited by 816 · cited 1×
“After drug administration and during the insulin clamp, nonsteady-state conditions for 3-3 H-glucose–specific activity prevail and the rate of glucose appearance ( R a ) was calculated with Steele’s equation (28).”
Groop, L. C., Bonadonna, R. C., DelPrato, S., Ratheiser, K., Zyck, K., Ferrannini, E., & DeFronzo, R. A. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114142 · Cited by 812 · cited 1×
“However, these latter studies are difficult to interpret, since insulin therapy also exerts other metabolic effects, e.g., reduction in plasma free fatty acid concentration (12), which profoundly affect insulin sensitivity independent of changes in plasma glucose concentration (13).”
Self-citationRossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Self-citationRossetti, L., Giaccari, A., & DeFronzo, R. A. (1990) · Diabetes Care · doi:10.2337/diacare.13.6.610 · Cited by 770
Self-citationDeFronzo, R. A., Ferrannini, E., & Simonson, D. C. (1989) · Metabolism · doi:10.1016/0026-0495(89)90129-7 · Cited by 515 · cited 1×
“Because of the close relationship between EGP (primarily reflects liver) and the fasting plasma glucose concentration (17), the decrease in FPG brought about by dapagliflozin would be expected to be associated with a decrease in HGP.”
Self-citationBanting Lecture 1997. Control of glucose uptake and release by the liver in vivo.
Cherrington, A. D. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1198 · Cited by 502
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Abdul-Ghani, M. A., Norton, L., & DeFronzo, R. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0029 · Cited by 443 · cited 1×
“…the impact of chronic hyperglycemia on insulin sensitivity in individuals with T2DM, we examined the effect of lowering the plasma glucose concentration on whole body insulin sensitivity by inhibiting renal sodium-glucose cotransport with dapagliflozin (15) using the insulin clamp technique.”
Self-citationDose-Response Effect of Elevated Plasma Free Fatty Acid on Insulin Signaling
Belfort, R., Mandarino, L., Kashyap, S., Wirfel, K., Pratipanawatr, T., Berria, R., DeFronzo, R. A., & Cusi, K. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1640 · Cited by 404 · cited 1×
“However, these latter studies are difficult to interpret, since insulin therapy also exerts other metabolic effects, e.g., reduction in plasma free fatty acid concentration (12), which profoundly affect insulin sensitivity independent of changes in plasma glucose concentration (13).”
Self-citation
Research works printed but not linked: 1
- Del Prato S, Leonetti F, Simonson DC, Sheehan P, Matsuda M, DeFronzo RA. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia. 1994;37(10):1025-1035. · DOI · Paper page
Cited by
Items 401–500 of 789
Inaba, Y., Hashiuchi, E., Watanabe, H., Kimura, K., Sato, M., Kobayashi, M., Matsumoto, M., Kitamura, T., Kasuga, M., & Inoue, H. (2019) · Endocrinology · doi:10.1210/en.2019-00422 · Cited by 18
SGLT2 Inhibitors and the Mechanisms Involved in Weight Loss
Feder, D., Gouveia, M. R. D. F. V., Govato, T. C. P., & Nassis, C. D. Z. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00236-3 · Cited by 22
Cho, Y. K., Kim, K. S., Lee, B., Hong, J. H., Yu, J. M., Lim, S. K., Kim, Y. A., Lee, C. B., Kim, S. S., Kwak, S. H., et al. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.06.023 · Cited by 20
Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes
Tan, X., & Hu, J. (2016) · Annales d Endocrinologie · doi:10.1016/j.ando.2015.11.003 · Cited by 19
Vakkalagadda, B. J., Vetter, M. L., Rana, J., Smith, C. H., Huang, J., Karkas, J., Boulton, D. W., & LaCreta, F. P. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.201 · Cited by 18
“Combination therapies are effective because they target different underlying pathophysiologic aspects of the disease to achieve additive, synergistic, or complementary glucose-lowering effects (Bailey and Day 2009; Merovci et al. 2014).”
Forst, T. M., Falk, A. C., Andersen, G., Fischer, A., Weber, M. M., Voswinkel, S., Heise, T., Kapitza, C., & Plum‐Mörschel, L. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12838 · Cited by 22
ALFORD, F. P., Henriksen, J. E., Rantzau, C., & Beck‐Nielsen, H. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2989 · Cited by 20
Lee, J.-Y., Cho, Y., Lee, M., Kim, Y. J., Lee, Y., Lee, B., Soo, B., & Kang, E. S. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0057 · Cited by 21
Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
Papakitsou, I., Vougiouklakis, G., Elisaf, M., & Filippatos, T. D. (2019) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s172353 · Cited by 29
“SGLT2 inhibitors induce glucagon release and reduce insulin resistance leading to an increased glucagon/insulin ratio that induces ketone reabsorption in the renal tubules, thus increasing the concentration of ketone bodies.(11,87) This mild increase in ketone levels possibly represents a mechanism of cardioprotection…”
BackgroundDapagliflozin restores insulin and growth hormone secretion in obese mice
Huang, Z., Huang, L., Wang, C., Zhu, S., Qi, X., Chen, Y., Zhang, Y., Cowley, M. A., Veldhuis, J. D., & Chen, C. (2020) · Journal of Endocrinology · doi:10.1530/joe-19-0385 · Cited by 18
The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition
Hædersdal, S., Lund, A., Nielsen-Hannerup, E., Maagensen, H., van Hall, G., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2020) · Diabetes · doi:10.2337/db20-0369 · Cited by 18
Investigation into the role of anti-diabetic agents in cachexia associated with metastatic cancer
Bora, V. R., & Patel, B. M. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119329 · Cited by 19
Avogaro, A., Giaccari, A., Fioretto, P., Genovese, S., Purrello, F., Giorgino, F., & Prato, S. D. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1322507 · Cited by 17
Abdelgadir, E., Rashid, F., Bashier, A. M., & Ali, R. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3467w · Cited by 23
Yamada, T., Sakaguchi, K., Okada, Y., Miura, H., Otowa‐Suematsu, N., So, A., Komada, H., Hirota, Y., Ohara, T., Kuroki, Y., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00474-2 · Cited by 17
Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus
Wolf, V. L. W., Breder, I. S. S., de Carvalho, L. S. F., Soares, A., Cintra, R. M. R., Barreto, J., Munhoz, D., Kimura-Medorima, S. T., Nadruz, W., Guerra‐Júnior, G., et al. (2021) · Nutrition and Diabetes · doi:10.1038/s41387-021-00160-5 · Cited by 21
Abdel‐Wahab, B. A., El‐Shoura, E. A. M., Habeeb, M. S., & Zaafar, D. K. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111325 · Cited by 17
Empagliflozin/linagliptin single‐tablet combination: first‐in‐class treatment option
Woo, V. C. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12720 · Cited by 19
Lam, K. S. L., Chow, C. C., Tan, K. C. B., Ronald, C. W., Kong, A. P. S., Tong, P. C. Y., Tsang, M. W., Chan, T. M., Tang, S. C. W., Lee, K. K., et al. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1161608 · Cited by 20
Personalized Therapy by Phenotype and Genotype
Lyssenko, V., Bianchi, C., & Prato, S. D. (2016) · Diabetes Care · doi:10.2337/dcs15-3002 · Cited by 19
Kusunoki, M., Natsume, Y., Miyata, T., Tsutsumi, K., & Oshida, Y. (2018) · Drug Research · doi:10.1055/a-0585-0145 · Cited by 17
“…first pointed out by Merovci et al. that SGLT2 inhibitor therapy with concomitant use of an insulin-secretion-facilitating DPP-4 inhibitor would be effective in the treatment of diabetes mel - litus, since SGLT2 inhibitors promote glucagon secretion to increase endogenous glucose production [11].”
Matsubayashi, Y., Yoshida, A., Suganami, H., OSAWA, T., Furukawa, K., Suzuki, H., Fujihara, K., Tanaka, S., Kaku, K., & Sone, H. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13980 · Cited by 18
Curtis, L. R., Humayun, M. A., Walker, J., Hampton, K., & Partridge, H. (2016) · Practical Diabetes · doi:10.1002/pdi.2018 · Cited by 17
Bouter, K. E. C., van Bommel, E. J. M., Jansen, H., van Harskamp, D., Schierbeek, H., Ackermans, M. T., Serlie, M. J. M., Schimmel, A. W. M., Nieuwdorp, M., Dallinga‐Thie, G. M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13990 · Cited by 19
Succurro, E., Vizza, P., Papa, A., Miceli, S., Cicone, F., Fiorentino, T. V., Sciacqua, A., Andreozzi, F., Veltri, P., Cascini, G. L., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14816 · Cited by 16
Self-citationFakhrolmobasheri, M., Abhari, A. P., Manshaee, B., Heidarpour, M., Shafie, D., Mohammadbeigi, E., Mozafari, A. M., & Mazaheri‐Tehrani, S. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01981-1 · Cited by 19
Torimoto, K., Okada, Y., Koikawa, K., & Tanaka, Y. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0258-5 · Cited by 17
“SGLT2 inhibitors have been reported to promote glucagon production [18, 19], which may limit the likelihood of development of hypoglycemia.”
BackgroundCersósimo, E., & Miles, J. M. (2018) · Current Diabetes Reviews · doi:10.2174/1573399814666180813124645 · Cited by 18
Nagashima, S., Wakabayashi, T., Saito, N., Takahashi, M., Okada, K., Ebihara, K., & Ishibashi, S. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13241 · Cited by 16
Cardiovascular effects and mechanisms of sodium‐glucose cotransporter‐2 inhibitors
Yang, F., Meng, R., & Zhu, D. (2020) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2020.07.002 · Cited by 19
DeFronzo, R. A., Ferrannini, E., Schernthaner, G., Hantel, S., Elsasser, U., Lee, C. S., Hach, T., & Lund, S. S. (2018) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.16 · Cited by 17
Self-citationSun, Y., Yan, D., Hao, Z., Cui, L., & Li, G. (2020) · Medical Science Monitor · doi:10.12659/msm.921891 · Cited by 16
Guthrie, R. M. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1044756 · Cited by 19
“facilitate plasma glucose lowering [94].”
Combination therapy with SGLT2 inhibitors for diabetic kidney disease
Cai, Y., Liu, X., & Xu, G. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110192 · Cited by 17
Hashiuchi, E., Watanabe, H., Kimura, K., Matsumoto, M., Inoue, H., & Inaba, Y. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13319 · Cited by 17
SGLT2i increased the plasma fasting glucagon level in patients with diabetes: A meta-analysis
Zhu, X., Lin, C., Li, L., Hu, S., Cai, X., & Ji, L. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174145 · Cited by 16
Tecce, N., de Alteriis, G., de Alteriis, G., Verde, L., Tecce, M. F., Colao, A., & Muscogiuri, G. (2024) · Healthcare · doi:10.3390/healthcare12070753 · Cited by 17
Kadowaki, T., Inagaki, N., Kondo, K., Nishimura, K., Kaneko, G., Maruyama, N., Nakanishi, N., Watanabe, Y., Gouda, M., & Iijima, H. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13038 · Cited by 16
Dapagliflozin Does Not Directly Affect Human α or β Cells
Dai, C., Walker, J. T., Shostak, A., Bouchi, Y. H., Poffenberger, G., Hart, N. J., Jacobson, D. A., Calcutt, M. W., Bottino, R., Greiner, D. L., et al. (2020) · Endocrinology · doi:10.1210/endocr/bqaa080 · Cited by 16
Ali, A. M., Mari, A., MARTINEZ, R. A., Jobori, H. A., Adams, J. M., Triplitt, C. L., DeFronzo, R. A., Cersósimo, E., & Abdul‐Ghani, M. A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa494 · Cited by 16
Self-citationCarpentieri, G. B., Gonçalves, S. E. A. B., Casagrande, M. Z., Mourad, W. M., Pinto, L. G. C., & Zanella, M. T. (2022) · Obesity Surgery · doi:10.1007/s11695-022-06119-4 · Cited by 18
Singh, A. K., & Singh, R. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.176353 · Cited by 18
SGLT2 inhibition and ketoacidosis – should we be concerned?
Rajeev, S. P., & Wilding, J. P. H. (2015) · The British Journal of Diabetes · doi:10.15277/bjdvd.2015.047 · Cited by 16
Ordelheide, A.-M., Böhm, A., Kempe-Teufel, D., Wagner, R., Machicao, F., Heni, M., Stefan, N., Fritsche, A., Häring, H.-U., & Staiger, H. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177148 · Cited by 14
Dong, M., Chen, H., Wen, S., Yuan, Y., Yang, L., Li, Y., Yuan, X., Xu, D., & Zhou, L. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s399367 · Cited by 20
Rajeev, S. P., Roberts, C. A., Brown, E. E., Sprung, V. S., Harrold, J. A., Halford, J. C. G., Stančák, A., Boyland, E. J., Kemp, G. J., Perry, J., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15257 · Cited by 17
“Further analysis using the mathematical models provided by 31,32 The modest weight loss with dapagliflozin treatment was associated with a significant reduction in MRI-determined liver fat, although not in abdominal VAT and SAT volumes.”
MethodJahn, L. A., Hartline, L. M., Nguyen, T. T. D., Aylor, K. W., Horton, W. B., Liu, Z., & Barrett, E. J. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00267.2023 · Cited by 17
Buras, E. D., Yang, L., Saha, P. K., Kim, J., Mehta, P., Yang, Y., Hilsenbeck, S. G., Kojima, H., Chen, W., Smith, C. W., et al. (2015) · The FASEB Journal · doi:10.1096/fj.15-271452 · Cited by 14
“Indeed, administration of insulin (46), or specific inhibitors of sodium/glucose cotransporters-2 located in the proximal nephrons such as empagliflozin (47) and dapagliflozin (48), not only decreased plasma glucose levels but also improved insulin sensitivity in type 2 diabetes patients.”
BackgroundBell, D. S. H. (2014) · American Journal of Case Reports · doi:10.12659/ajcr.890626 · Cited by 14
Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin
Aronson, R. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1027185 · Cited by 15
“Merovci et al. hypothesized that combining an SGLT2 inhibitor with a DPP-4 inhibitor or GLP-1 analog would produce an additive or possibly synergistic effect to improve glycemic parameters57.”
InfluentialInsulin resistance: Impact on therapeutic developments in diabetes
Bailey, C. J. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164119827570 · Cited by 14
“SGLT2 inhibitors introduced in 2012 reduce glucotoxicity and adiposity by eliminating excess glucose in the urine, and thereby act indirectly to reduce insulin resistance and spare some of the demand on beta-cell function [30, 31].”
BackgroundSchnell, O., Valensi, P. E., Standl, E., & Ceriello, A. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.129 · Cited by 15
Chábová, V. Č., & Zakiyanov, O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052812 · Cited by 18
Okajima, F., Nagamine, T., Nakamura, Y., Hattori, N., Sugihara, H., & Emoto, N. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12588 · Cited by 14
Alsalim, W., Persson, M., & Åhrén, B. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13276 · Cited by 21
Lin, Y.-H. (2018) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.02.004 · Cited by 14
Pancholia, A. K. (2018) · Indian Heart Journal · doi:10.1016/j.ihj.2018.08.022 · Cited by 18
Pathogenesis of Type 2 Diabetes Mellitus
DeFronzo, R. A. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_8 · Cited by 16
Self-citationKoufakis, T., Metallidis, S., Zebekakis, P. E., Ajjan, R., & Kotsa, K. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820932155 · Cited by 14
Burns, J. M., Morris, J. K., Vidoni, E. D., Wilkins, H., Choi, I., Lee, P., Hunt, S. L., Mahnken, J. D., Brooks, W. M., Lepping, R. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70416 · Cited by 19
Jain, A., Vispute, A., Dange, A., Naskar, A., Mondal, A., Vivekanand, B., Sharma, B., Varade, D., Shukla, D., Bhatia, G., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01504-3 · Cited by 14
Autophagy-lysosome pathway in insulin & glucagon homeostasis
Wu, Y., Wang, H., & Xu, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1541794 · Cited by 23
Goldenberg, R., Verma, S., Perkins, B. A., Gilbert, J. D., & Zinman, B. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.08.001 · Cited by 13
Huh, Y., & Kim, Y. S. (2022) · BMC Family Practice · doi:10.1186/s12875-022-01748-1 · Cited by 16
LP ‐925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT 1 and SGLT 2
Powell, D. R., Smith, M. G., Doree, D. D., Harris, A. L., Xiong, W., Mseeh, F., Wilson, A., Gopinathan, S., Diaz, D. S., Goodwin, N. C., et al. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.129 · Cited by 13
“Also, the possibility that the benefits of increased UGE may be offset by increased endogenous glucose production, as occurred during oral administration of SGLT2 inhibitors (Ferrannini et al. 2014; Merovci et al. 2014), must also be evaluated.”
BackgroundNojima, T., Matsubayashi, Y., Yoshida, A., Suganami, H., Abe, T., Ishizawa, M., Fujihara, K., Tanaka, S., Kaku, K., & Sone, H. (2020) · Diabetic Medicine · doi:10.1111/dme.14279 · Cited by 13
The dual role of empagliflozin: Cardio renal protection in T2DM patients
Shafiq, A., Mahboob, E., Samad, M. A., Rehman, M. H. U., & Tharwani, Z. H. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.104555 · Cited by 16
Cersósimo, E., Alatrach, M., Solis‐Herrera, C., Baskoy, G., Adams, J. M., HANSIS-DIARTE, A. A., Gastaldelli, A., Chávez, A. O., Triplitt, C. L., & DeFronzo, R. A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad438 · Cited by 14
Self-citationGöpel, S., Adingupu, D. D., Wang, J., Semenova, E., Behrendt, M., Jansson‐Löfmark, R., Ahlström, C., Jönsson‐Rylander, A., Gopaul, V. S., ESTERLINE, R. L., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02491-w · Cited by 14
“Based on the above and the fact that SGLT2 inhibitors increase glucagon levels [26, 27], a feature that to our knowledge is not shared by any other blood glucose lowering drug, we investigated in our current studies the contribution of glucagon signaling to improvements in CV function.”
Mudali, D., Jeevanandam, J., & Danquah, M. K. (2020) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2020.1789062 · Cited by 12
Koike, M., Saito, H., Kohno, G., Takubo, M., Watanabe, K., & Ishihara, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111463 · Cited by 12
Okura, T., Fujioka, Y., Nakamura, R., Kitao, S., Ito, Y., Anno, M., Matsumoto, K., Shoji, K., Matsuzawa, K., Izawa, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-05704-y · Cited by 16
Perspectives in weight control in diabetes – SGLT2 inhibitors and GLP-1–glucagon dual agonism
Iqbal, N., Ambery, P., Logue, J., Mallappa, A., & Sjöström, C. D. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110669 · Cited by 14
Singh, A. K., & Singh, R. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1123616 · Cited by 12
Kinoshita, T., Shimoda, M., Sanada, J., Fushimi, Y., Hirata, Y., Irie, S., Obata, A., Kimura, T., Hirukawa, H., Kohara, K., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0447-8 · Cited by 12
Dokmak, A., Almeqdadi, M., Trivedi, H. D., & Krishnan, S. (2019) · World Journal of Hepatology · doi:10.4254/wjh.v11.i7.562 · Cited by 15
Koomen, J. V., Stevens, J., & Heerspink, H. J. L. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14318 · Cited by 13
Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences
Singh, A. K., & Singh, R. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1131121 · Cited by 12
Yu, H. J., & Woo, V. C. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s117982 · Cited by 14
“Although both lower PPG, DPP4 inhibitors result in a greater decrement after taking into account their respective fasting glucose-lowering effects(29) and inhibit the increased glucagon production seen with dapagliflozin.(16,17) The five completed phase III trials have demonstrated additional glycemic-lowering benefit…”
Ryan, S. P. P., Newman, A. A., Wilburn, J. R., Rhoades, L. D., Trikha, S. R. J., Godwin, E. C., Schoenberg, H. M., Battson, M. L., Ewell, T. R., Luckasen, G. J., et al. (2020) · Nutrients · doi:10.3390/nu12020510 · Cited by 14
Imaging of Sarcopenia in Type 2 Diabetes Mellitus
Wang, D., Zhang, G., Yu, Y., & Zhang, Z. (2024) · Clinical Interventions in Aging · doi:10.2147/cia.s443572 · Cited by 11
“30,31 Epidemiological research indicates a link between thiazolidinediones and reduced loss of muscle mass as well as improved walking pace among patients with T2DM.”
BackgroundLong-term effects of canagliflozin treatment on the skeleton of aged UM-HET3 mice
Yildirim, G., Bergamo, E. T. P., Poudel, S. B., Ruff, R. R., Dixit, M., Hu, B., Mijares, D. Q., Witek, L., Chlebek, C., Harrison, D. E., et al. (2023) · GeroScience · doi:10.1007/s11357-023-00803-8 · Cited by 12
“changes in whole-body metabolism including glucose utilization, hormonal responses (insulin/glucagon ratio) [51], substrate selection (lipid vs carbohydrates) [52–55], and probably energy expenditure, all which have indirect effects on bone metabolism.”
Seksaria, S., Dutta, B. J., Kaur, M., Gupta, G. D., Bodakhe, S. H., & Singh, A. (2023) · Current Diabetes Reviews · doi:10.2174/1573399820666230809152148 · Cited by 12
Baekdal, M., Nielsen, S. W., Hansen, C. P., Storkholm, J. H., van Hall, G., Hartmann, B., Holst, J. J., Vilsbøll, T., Lund, A., & Knop, F. K. (2023) · Diabetes Care · doi:10.2337/dc23-0645 · Cited by 11
Effect of Hyperketonemia on Myocardial Function in Patients With Heart Failure and Type 2 Diabetes
Solis‐Herrera, C., Qin, Y., Honka, H., Cersósimo, E., Triplitt, C. L., Neppala, S., Rajan, J., Acosta, F. M., Moody, A. J., Iozzo, P., et al. (2024) · Diabetes · doi:10.2337/db24-0406 · Cited by 14
“We and others have shown that SGLT2i treatment of patients with T2DM consistently increases the fasting plasma ketone concentration two-to fourfold (29,30), and ketone levels > 1 mmol/L have been reported in 15 – 20% of patients with diabetes treated with an SGLT2i for 52 weeks (31).”
Self-citationHong, B., Lee, H., Jung, K., Rhee, S. Y., Yon, D. K., & Shin, J. (2025) · BMJ · doi:10.1136/bmj-2025-085196 · Cited by 15
Harati, H., Sharma, V. R., & Motazedi, A. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12330 · Cited by 11
Canagliflozin for the treatment of adults with Type 2 diabetes
Meininger, G. E., Canovatchel, W. J., Polidori, D., & Rosenthal, N. (2015) · Diabetes Management · doi:10.2217/dmt.15.11 · Cited by 11
Nuevos hipoglucemiantes orales y riesgo cardiovascular. Cruzando la frontera metabólica
Dalama, B., & Mesa, J. (2016) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.07.029 · Cited by 12
Abdul‐Ghani, M. A., Migahid, O., Megahed, A., Singh, R., Fawaz, M., DeFronzo, R. A., & Jayyousi, A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13546 · Cited by 13
Self-citationAnti-inflammatory and atheroprotective properties of glucagon
Osaka, N., Kushima, H., Mori, Y., Saito, T., Hiromura, M., Terasaki, M., Yashima, H., Ohara, M., Fukui, T., Matsui, T., et al. (2020) · Diabetes and Vascular Disease Research · doi:10.1177/1479164120965183 · Cited by 12
Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
Armour, S. L., Frueh, A., & Knudsen, J. G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.837664 · Cited by 13
“These findings suggest that SGLT1 plays a central role for glucagon secretion in response to glucose and provides a potential explanation for increased circulating glucagon seen in some patients on SGLT2 inhibitors (Ferrannini et al., 2014; Merovci et al., 2014).”
BackgroundEl‐Megharbel, S. M., Althubaiti, E. H., Qahl, S. H., Al-Eisa, R. A., & Hamza, R. Z. (2022) · Crystals · doi:10.3390/cryst12030304 · Cited by 12
Potential Place of SGLT2 Inhibitors in Treatment Paradigms for type 2 Diabetes Mellitus
Handelsman, Y. (2015) · Endocrine Practice · doi:10.4158/ep15703.ra · Cited by 13
Short commentary on empagliflozin and its potential clinical impact
Hinnen, D. A. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018815578599 · Cited by 13
Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
Davis, S. N., & Munir, K. M. (2016) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s77754 · Cited by 16
“However, improvements in insulin-mediated whole body glucose uptake shown via euglycemic-hyperinsulinemic clamp in individuals treated with dapagliflozin, likely due to amelioration of glucotoxicity, provide evidence that SGLT2 inhibition also has an indirect effect on insulin sensitivity.(10)”
Clemmensen, K. K. B., Blond, M. B., Amadid, H., Bruhn, L., Vistisen, D., Karstoft, K., Persson, F., Ried‐Larsen, M., Holst, J. J., Albrechtsen, N. J. W., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14246 · Cited by 13
Brown, E. E., Wilton, M., Sprung, V. S., Harrold, J. A., Halford, J. C. G., Stančák, A., Burgess, M. I., Howarth, E., Umpleby, A. M., Kemp, G. J., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-045663 · Cited by 13
Lee, M. H., Neeland, I. J., Rocha, N. D. A., Hughes, C., Malloy, C. R., & Jin, E. S. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100161 · Cited by 12
Alatrach, M., Agyin, C., Solis‐Herrera, C., Lavryneko, O., Adams, J. M., Gastaldelli, A., Triplitt, C. L., DeFronzo, R. A., & Cersósimo, E. (2022) · Diabetes Care · doi:10.2337/dc21-1798 · Cited by 11
Self-citation
Metadata
- Authors
- Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., & DeFronzo, R. A.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- DeFronzo, Ralph A.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-01-27
- Volume
- 124
- Issue
- 2
- Pages
- 509-514
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3904617
- OpenAlex
- W2166613497
- Cited by
- 795
- References
- 28
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 52 · 2023: 55 · 2022: 64 · 2021: 58 · 2020: 91 · 2019: 63 · 2018: 71 · 2017: 71 · 2016: 79 · 2015: 82 · 2014: 43
- FWCI
- 73.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- National Institutes of Health (UL1TR001120, 5R01DK240923, KL2TR001118)
- University of Texas Health Science Center at San Antonio
- National Institute of Diabetes and Digestive and Kidney Diseases (5R01DK240923, R01DK024092)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, skeletal muscle insulin sensitivity, endogenous glucose production, glycosuria, glucotoxicity, hyperglycemia, insulin-stimulated glucose disposal, glucagon, renal glucose transport
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Fasting, Glucagon, Glucose, Glucosides, Humans, Hyperglycemia, Insulin, Male, Metformin, Middle Aged, Muscles, Sulfonylurea Compounds, Time Factors, Glucose Clamp Technique, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.